Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/229569
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Pathogenic SREK1 decrease in Huntington's disease lowers TAF1 mimicking X-linked dystonia parkinsonism |
Autor: | Hernández, Ivó H.; Cabrera, Jorge Rubén CSIC ORCID CVN; Santos-Galindo, María CSIC ORCID; Sánchez-Martín, Manuel; Domínguez, Verónica; García-Escudero, Ramón CSIC ORCID; Pérez-Álvarez, María José CSIC ORCID; Pintado, Belén; Lucas, José Javier CSIC ORCID | Palabras clave: | SREK1 TAF1 RNA-binding proteins (RBP) Splicing SR proteins |
Fecha de publicación: | jul-2020 | Editor: | Oxford University Press | Citación: | Brain, a journal of neurology 143(7): 2207-2219 (2020) | Resumen: | Huntington’s disease and X-linked dystonia parkinsonism are two monogenic basal ganglia model diseases. Huntington’s disease is caused by a polyglutamine-encoding CAG repeat expansion in the Huntingtin (HTT) gene leading to several toxic interactions of both the expanded CAG-containing mRNA and the polyglutamine-containing protein, while X-linked dystonia parkinsonism is caused by a retrotransposon insertion in the TAF1 gene, which decreases expression of this core scaffold of the basal transcription factor complex TFIID. SRSF6 is an RNA-binding protein of the serine and arginine-rich (SR) protein family that interacts with expanded CAG mRNA and is sequestered into the characteristic polyglutamine-containing inclusion bodies of Huntington’s disease brains. Here we report decreased levels of the SRSF6 interactor and regulator SREK1—another SR protein involved in RNA processing—which includes TAF1 as one of its targets. This led us to hypothesize that Huntington’s disease and X-linked dystonia parkinsonism pathogeneses converge in TAF1 alteration. We show that diminishing SRSF6 through RNA interference in human neuroblastoma cells leads to a decrease in SREK1 levels, which, in turn, suffices to cause diminished TAF1 levels. We also observed decreased SREK1 and TAF1 levels in striatum of Huntington’s disease patients and transgenic model mice. We then generated mice with neuronal transgenic expression of SREK1 (TgSREK1 mice) that, interestingly, showed transcriptomic alterations complementary to those in Huntington’s disease mice. Most importantly, by combining Huntington’s disease and TgSREK1 mice we verify that SREK1 overexpression corrects TAF1 deficiency and attenuates striatal atrophy and motor phenotype of Huntington’s disease mice. Our results therefore demonstrate that altered RNA processing upon SREK1 dysregulation plays a key role in Huntington’s disease pathogenesis and pinpoint TAF1 as a likely general determinant of selective vulnerability of the striatum in multiple neurological disorders. | Descripción: | The Author(s) (2020). | Versión del editor: | http://dx.doi.org/10.1093/brain/awaa150 | URI: | http://hdl.handle.net/10261/229569 | DOI: | 10.1093/brain/awaa150 | ISSN: | 0006-8950 | E-ISSN: | 1460-2156 |
Aparece en las colecciones: | (CNB) Artículos (CBM) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Pathogenic_Hernandez_PV_Art2020.pdf | 1,31 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
9
checked on 11-abr-2024
SCOPUSTM
Citations
15
checked on 20-abr-2024
WEB OF SCIENCETM
Citations
13
checked on 28-feb-2024
Page view(s)
103
checked on 23-abr-2024
Download(s)
91
checked on 23-abr-2024